Clinical trials
Allogeneic Disease clinical trials
Below are recruiting allogeneic disease clinical trials, each written for real people, not researchers. We’re tracking 92 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05854615RecruitingPhase 4
Stem cell treatment for painful poor blood flow in limbs
This trial tests whether a stem cell product (Stempeucel®) is safe and effective for people with Buerger’s disease causing critical limb ischemia and foot ulcers. It may help improve healing and blood flow when other options may be limited.
Kuala LumpurAges 18–65 - NCT07367815RecruitingPhase 1/Phase 2
Stem cells from fat tissue for Alzheimer's disease
This trial tests whether stem cells from donated fat tissue can help people with mild to moderate Alzheimer's disease. It combines infusions of these cells with standard care, and includes brain scans and memory tests to see if the treatment is safe and effective.
ToulouseAges 50–85 - NCT01852370Enrolling by invitationPhase 1/Phase 2
Lung and bone marrow transplant plan for immune system disorders
This early-phase study tests a step-by-step transplant approach: first replacing the lungs, then doing a bone marrow (stem cell) transplant to treat certain immune deficiency diseases. It may help people whose immune problem has led to severe, end-stage lung disease.
Pittsburgh, PennsylvaniaAges 5–45 - NCT05463133RecruitingPhase 1/Phase 2
Stem cell transplant for CGD using targeted medications and steroids-free support
This trial tests an intensive stem cell transplant approach for people with chronic granulomatous disease (CGD). The study aims to improve outcomes by preparing the body for a donor stem cell graft and using immune “brakes” to reduce immune problems.
Bethesda, MarylandAges 4–65 - NCT07126782RecruitingEarly Phase 1
Gene-edited immune cells for AML after transplant
This trial tests a type of immune cell called gamma-delta T cells in people with acute myeloid leukemia who still have minimal residual disease after a stem cell transplant. The goal is to see if these cells can clear the remaining leukemia cells safely and effectively.
BeijingAges 18 years+ - NCT05800210RecruitingPhase 2
T cell and B cell immune “wipeout” after stem cell transplant
This Phase 2 trial studies whether removing certain immune cells (alpha/beta T cells and CD19+ B cells) around the time of a stem cell transplant can improve outcomes for people with high-risk blood cancers. It may help by reducing the immune responses that can interfere with the transplant working, while keeping the process safe.
Gainesville, FloridaAges 6 months–39 years - NCT06128070RecruitingPhase 2
Preventing GVHD after stem cell transplant for leukemia
This trial tests adding ruxolitinib to standard drugs (tacrolimus and methotrexate) to prevent graft-versus-host disease in children and young adults undergoing a stem cell transplant for acute leukemia or myelodysplastic syndrome. The goal is to lower the risk of GVHD and improve transplant outcomes.
Duarte, CaliforniaAges 2–22 - NCT06919081RecruitingPhase 2
Stem cell eye drops for chronic cornea problems
This study tests whether a special substance from stem cells (called secretome) can help heal chronic surface problems on the eye that haven't gotten better with standard treatments. It's for people with a stubborn scratch or defect on the cornea that has lasted more than 14 days.
Chicago, IllinoisAges 18 years+ - NCT07613099RecruitingPhase 3
Testing a new PET scan to detect lung and heart scarring
This study tests a new imaging scan (called 18F-FAPI PET/CT) that may help detect scarring in the lungs, heart, or blood vessels. If you have a heart, lung, or blood vessel condition that could cause scarring, this scan might show damage earlier and help doctors plan better treatment.
Bethesda, MarylandAges 18–100 - NCT05147688RecruitingPhase 1
Safety study of donor stem cell treatment for lung disease
This early study tests whether donor stem cells made from umbilical cord tissue are safe in people with lung diseases. If you qualify, you may be offered the study treatment while the team closely checks for side effects and safety.
St John'sAges Any age - NCT05147779RecruitingPhase 1
Stem cell treatment safety study for multiple bladder and sexual conditions
This Phase 1 trial tests whether lab-grown stem cells made from umbilical-cord tissue are safe in people with Peyronie’s disease, erectile dysfunction, or interstitial cystitis. It may help by showing whether this approach is tolerated and safe, before larger studies test how well it works.
St John'sAges Any age - NCT03394365RecruitingPhase 3
Tabelecleucel for EBV-related lymphoma after transplant treatment failure
This trial tests tabelecleucel, an immune therapy, for people whose EBV-associated post-transplant lymphoproliferative disease (PTLD) did not respond to rituximab and/or chemotherapy. It may help your immune system better control EBV-driven lymphoma after a transplant.
Duarte, CaliforniaAges Any age - NCT06828796RecruitingPhase 2
Early tacrolimus with half-matched stem cell transplant for blood cancer
This trial tests whether giving tacrolimus early after a half-matched donor stem cell transplant can improve outcomes for patients with blood cancer. The donor must be a family member who shares about half of your HLA markers.
Atlanta, GeorgiaAges 18–80 - NCT07115745RecruitingPhase 1
Donor CAR T cells for severe autoimmune diseases
This study tests a new type of CAR T-cell therapy made from healthy donor cells. It is designed to help people with severe autoimmune diseases that have not improved with standard treatments.
Boston, MassachusettsAges 18 years+ - NCT05039411RecruitingPhase 1
Cord stem cell treatment for Crohn’s perianal fistulas
This Phase 1 study tests whether donor umbilical cord stem cells are safe for treating fistulas (abnormal tunnels) near the anus in people with Crohn’s disease. It’s mainly looking at safety, and it may help some people’s symptoms if the approach is workable.
Kuala LumpurAges 18 years+ - NCT07085104RecruitingPhase 1
Study of ALLO-329 for lupus, myositis, or scleroderma
This trial tests a new one-time cell therapy (ALLO-329) made from donor cells to target and calm overactive immune cells in people with lupus, myositis, or scleroderma that hasn't improved with usual medications. It aims to see if this treatment is safe and can help reduce disease activity.
Phoenix, ArizonaAges 18–74 - NCT07507201RecruitingEarly Phase 1
Car-T cells for autoimmune diseases like lupus
This trial tests whether specially-engineered immune cells (CAR-T cells) can help people with certain autoimmune diseases that haven't gotten better with standard treatments. The cells are designed to target and remove faulty B cells that are causing the immune system to attack the body.
Hangzhou, ZhejiangAges 3 years+ - NCT07490288Recruiting
Venetoclax, azacitidine, and mitoxantrone for new AML
This trial tests a combination of three drugs (venetoclax, azacitidine, and liposomal mitoxantrone) as a first treatment for people newly diagnosed with acute myeloid leukemia (AML). The goal is to see if this combination works better than standard care.
Tianjin, Tianjin MunicipalityAges 14–100 - NCT04496479RecruitingPhase 2
Transplanting donor liver cells near lymph nodes in advanced liver disease
This Phase 2 study tests whether transplanting donor liver cells near lymph nodes can improve outcomes in people with advanced cirrhosis from certain liver conditions. It may help your liver function by adding healthy liver cells, but eligibility is tightly based on your current liver status and other health factors.
Boston, MassachusettsAges 18–70 - NCT06715046Recruiting
Blood DNA test after stem cell transplant
This study checks if looking at DNA in your blood can help doctors see how well your stem cell transplant is working and catch any problems early. It is for people with blood cancers getting a transplant from a donor.
Milan, MilanAges 18 years+ - NCT06799195RecruitingPhase 2
Better GVHD prevention after stem cell transplant
This trial tests a new approach to prevent graft-versus-host disease (GVHD) after a stem cell transplant from a matched donor. It is for people aged 60 or older with a blood cancer or serious blood disorder who are getting a reduced-intensity conditioning regimen.
Omaha, NebraskaAges 60 years+ - NCT07028112Recruiting
Iron and liver health after stem cell transplant
This study looks at how too much iron in the body (from past transfusions) affects the liver in people who had a stem cell transplant at least 10 years ago. It will help doctors understand who needs special monitoring for liver problems.
ParisAges 18 years+ - NCT05152394RecruitingPhase 1
Testing cord stem cell exosome treatment for Parkinson’s safety
This Phase 1 study tests whether a treatment made from donated umbilical cord “exosomes” is safe in people with Parkinson’s disease. It mainly looks at side effects and safety, and could help guide future treatments if it proves tolerable.
St John'sAges Any age - NCT05147701RecruitingPhase 1
Testing stem cell treatment for NAION safety
This Phase 1 study tests whether lab-made stem cells taken from donated umbilical cord are safe for people with NAION. It mainly looks for side effects and safety rather than proving the treatment works.
St John'sAges Any age
Hear when a new Allogeneic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for allogeneic disease?
- Yes. Clin2 currently lists 92 recruiting allogeneic disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a allogeneic disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a allogeneic disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.